SCHEMBL23978116

SCHEMBL23978116

COc1ccc(Nc2nc(Cl)ncc2CNc2c(C)csc2Cl)nc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV4 Q9HBA0 1/20 0.38
ALDH1A1 P00352 2/20 0.36
GAA P10253 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
CCND3 P30281 1/20 0.33
CDK6 Q00534 1/20 0.33
LCK P06239 1/20 0.32
NPC1 O15118 3/20 0.31
RAB9A P51151 3/20 0.31
KMT2A Q03164 2/20 0.31
MEN1 O00255 1/20 0.31
CCNE2 O96020 1/20 0.31
CCNE1 P24864 1/20 0.31
CDK2 P24941 1/20 0.31
LMNA P02545 2/20 0.31
DHFR P00374 1/20 0.31
CYP1A2 P05177 1/20 0.31
GLA P06280 1/20 0.31
CYP3A4 P08684 1/20 0.31
CYP2D6 P10635 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30309547 1.00 TRPV4 (0.38) TRPV4ALDH1A1GAATDP1CCND3
SCHEMBL23978127 0.89 TRPV4 (0.35) TRPV4ALDH1A1GAATDP1CCND3
SCHEMBL30309532 0.89 TRPV4 (0.35) TRPV4ALDH1A1GAATDP1CCND3
SCHEMBL30309543 0.87 TRPV4 (0.34) TRPV4ALDH1A1GAATDP1CCND3
SCHEMBL23978385 0.87 TRPV4 (0.34) TRPV4ALDH1A1GAATDP1CCND3
SCHEMBL23978358 0.85 LCK (0.41) ALDH1A1TDP1CCND3CDK6LCK
SCHEMBL30309599 0.85 LCK (0.41) ALDH1A1TDP1CCND3CDK6LCK
SCHEMBL23978179 0.80 CCND3 (0.36) TRPV4ALDH1A1CCND3CDK6NPC1
SCHEMBL23978363 0.80 CYP1A2 (0.39) TRPV4ALDH1A1CCND3CDK6LMNA
SCHEMBL30309501 0.80 CCND3 (0.36) TRPV4ALDH1A1CCND3CDK6NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230192701-A1 BICYCLIC KINASE INHIBITORS AND USES THEREOF IOMX THERAPEUTICS AG (DE) 2023-06-22 US disclosed
US-20230192701-A1 BICYCLIC KINASE INHIBITORS AND USES THEREOF IOMX THERAPEUTICS AG (DE) 2023-06-22 US disclosed
WO-2021219731-A2 BICYCLIC KINASE INHIBITORS AND USES THEREOF IOMX THERAPEUTICS AG (DE) 2021-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230192701-A1 BICYCLIC KINASE INHIBITORS AND USES THEREOF MITF, PRKDC, PRKACA TRPV4 3730/4885ALDH1A1 3047/4885GAA 3367/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.